WAY-151932 (VNA-932) (Synonyms: VNA-932; WAY-VNA 932) |
| カタログ番号GC31475 |
WAY-151932 (VNA-932) は、バソプレシン V2 受容体アゴニストであり、ヒト V2 結合および V1a 結合アッセイで IC50 が 80.3 nM および 778 nM です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 220460-92-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay.
WAY-151932 (VNA-932) stimulates cAMP formation in LV2 cells expressing the hV2 receptors in a dose-dependent manner with an EC50 of 0.74±0.07 nM[2].
Oral administration of WAY-151932 (VNA-932) to water-loaded conscious rats produces a dose-dependent decrease in urine volume (ED50=0.14 mg/kg, 2.5% starch in water vehicle) and a corresponding increase in osmolality without altering the urine electrolyte excretion profile[2].
[1]. Molinari AJ, et al. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5796-800. [2]. Failli AA, et al. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *